Benitec Biopharma (BNTC) Stock Price, News & Analysis

+0.02 (+0.21%)
(As of 05/17/2024 08:53 PM ET)
Today's Range
50-Day Range
52-Week Range
24,500 shs
Average Volume
62,493 shs
Market Capitalization
$88.90 million
P/E Ratio
Dividend Yield
Price Target

Benitec Biopharma MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
68.6% Upside
$16.00 Price Target
Short Interest
6.27% of Float Sold Short
Dividend Strength
News Sentiment
0.72mentions of Benitec Biopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

Medical Sector

731st out of 914 stocks

Pharmaceutical Preparations Industry

340th out of 427 stocks

BNTC stock logo

About Benitec Biopharma Stock (NASDAQ:BNTC)

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BNTC Stock Price History

BNTC Stock News Headlines

Why Benitec Biopharma Is Rising In Pre-market?
11 Best ASX Stocks To Buy Now
Benitec Biopharma Inc BNTC
JMP Securities Sticks to Its Buy Rating for Benitec Biopharma (BNTC)
See More Headlines
Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End
Next Earnings (Estimated)

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Price / Sales
Book Value
$1.23 per share


Free Float
Market Cap
$88.90 million
No Data
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Jerel A. Banks M.D. (Age 49)
    Ph.D., Executive Chairman & CEO
    Comp: $848.07k
  • Ms. Megan Joan Boston BComm (Age 52)
    CA, Dip., GAICD, Executive Director
    Comp: $439.17k
  • Dr. Michael Graham
    Head of Discovery & Founding Scientist
  • Dr. Claudia Kloth
    Senior Vice President of Manufacturing

BNTC Stock Analysis - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings
or view top-rated stocks.

What is Benitec Biopharma's stock price target for 2024?

1 equities research analysts have issued 1 year price objectives for Benitec Biopharma's shares. Their BNTC share price targets range from $16.00 to $16.00. On average, they anticipate the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 68.6% from the stock's current price.
View analysts price targets for BNTC
or view top-rated stocks among Wall Street analysts.

How have BNTC shares performed in 2024?

Benitec Biopharma's stock was trading at $3.23 on January 1st, 2024. Since then, BNTC shares have increased by 193.8% and is now trading at $9.49.
View the best growth stocks for 2024 here

When is Benitec Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, September 19th 2024.
View our BNTC earnings forecast

When did Benitec Biopharma's stock split?

Shares of Benitec Biopharma reverse split on the morning of Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).

When did Benitec Biopharma IPO?

Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (9.44%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNTC) was last updated on 5/20/2024 by Staff

From Our Partners